Teles AG Informationstechnologien (TLIK) AI Stock Analysis

• Market Cap: €1.88M
• Dividend Yield: N/A
• Average Volume (3M): 390.00
• Price to Earnings (P/E): ―
• Beta (1Y): -101.22
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: DE
• Employees: 2
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Distribution
• EPS (TTM): N/A
• Shares Outstanding: 6,233,418
• 10 Day Avg. Volume: 501
• 30 Day Avg. Volume: 390
• PEG Ratio: 0.08
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 5.45
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: €0.21 ▼(-37.58% Downside)
• Action: N/A Date: 01/14/26
• Date: Action: N/A 01/14/26

The score is held near the floor primarily by severely weakened financial performance (collapsed revenue, very large losses, ongoing cash burn, and a weakened balance sheet with higher debt and zero reported equity). Technicals add further pressure with price trading below key moving averages and negative MACD, while valuation metrics are not supportive due to a negative P/E and no dividend data.

Positive Factors

High gross margin

High gross profit relative to revenue indicates the company’s core offerings retain strong unit economics. Over a multi-month horizon, such margins give room to absorb fixed costs, speed recovery of operating profits if sales stabilize, and improve cash conversion as volumes recover.

Rising asset base

An increase in total assets since 2023 provides tangible resources that can support operational rebuilding or serve as collateral for financing. This enlarged base offers strategic optionality over months for restructuring, working capital, or asset-based funding to stabilize operations.

Historically clean capital structure

Past periods with positive equity and no debt show the company previously operated with conservative financing and rebuild potential. That history implies management has operated without heavy leverage, suggesting feasible pathways to reestablish a healthier balance sheet if execution and funding align.

Negative Factors

Collapsed revenue

A ~99% year-over-year revenue collapse is a severe structural impairment: it destroys scale, undermines customer and market relevance, and prevents effective absorption of fixed costs. Over months this materially raises the likelihood of prolonged losses and constrains recovery pathways.

Persistent negative cash flow

Consistent negative operating and free cash flow indicate ongoing cash burn that depletes reserves and forces reliance on external funding. Over a 2–6 month horizon this heightens refinancing, liquidity and covenant risks, limiting the firm’s ability to invest, market, or stabilize operations.

Deteriorated balance sheet / zero equity

A meaningful rise in debt alongside reported equity of zero removes the shareholders' cushion and increases leverage and insolvency risk. Without equity buffer, the company faces constrained financing options, weaker creditor negotiating power, and greater vulnerability to operational shocks over months.

Teles AG Informationstechnologien Business Overview & Revenue Model

Company Description

Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.

How the Company Makes Money

Teles AG Informationstechnologien Financial Statement Overview

Summary

Financials appear highly stressed: revenue collapsed (~99% decline in 2024 vs. 2023), losses are extreme (net losses larger than revenue), operating/free cash flow are persistently negative, and the balance sheet has deteriorated with higher debt and zero reported equity in the latest two annual reports.

Income Statement

Revenue has collapsed over the last two annual periods (down ~99% in 2024 vs. 2023), and profitability is deeply negative. Despite very high gross margin in 2024, operating losses are extreme (EBIT and EBITDA far below zero), and net losses are larger than revenue, indicating a cost structure that is not supported by the current sales base. The main positive is that gross profit remains high relative to revenue, but the earnings trajectory is sharply deteriorating.

Balance Sheet

The balance sheet shows a meaningful increase in total debt in 2024 versus 2023, while reported equity is zero in both of those years, which weakens financial flexibility and makes leverage risk harder to assess. Total assets have risen since 2023, but the lack of equity cushion in the most recent years is a key concern. Earlier periods showed positive equity and no debt, suggesting the capital structure has deteriorated materially.

Cash Flow

Cash generation is weak with operating cash flow negative in every shown year, and free cash flow also consistently negative. Free cash flow worsened further in 2024 versus 2023, reinforcing that the business is consuming cash rather than funding itself internally. While free cash flow is broadly in line with net income (both negative), the persistent cash burn heightens funding and liquidity risk if conditions do not improve.

Breakdown	TTM	Dec 2024	Mar 2024	Mar 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	-44.69M	657.55K	1.67M	2.67M	2.82M	4.16M
Gross Profit	-2.05M	657.47K	1.45M	2.17M	2.30M	2.17M
EBITDA	-1.06M	-661.20K	―	-237.78K	922.87K	2.16M
Net Income	-442.86K	-835.24K	-1.89M	-267.51K	824.51K	3.87M
Balance Sheet
Total Assets	4.61M	4.17M	3.30M	2.85M	1.18M	2.78M
Cash, Cash Equivalents and Short-Term Investments	5.18K	125.52K	82.11K	391.22K	751.55K	13.32K
Total Debt	0.00	636.00K	125.00K	0.00	0.00	173.00K
Total Liabilities	4.61M	4.17M	3.30M	1.24M	1.16M	2.78M
Stockholders Equity	0.00	0.00	0.00	1.61M	13.30K	―
Cash Flow
Free Cash Flow	-1.79M	-1.41M	-1.09M	-330.33K	-999.61K	―
Operating Cash Flow	-1.85M	-1.41M	-1.09M	-280.65K	-986.42K	―
Investing Cash Flow	-217.22K	-6.72K	0.00	-79.68K	-13.19K	0.00
Financing Cash Flow	1.19M	1.45M	1.13M	0.00	1.74M	600.00K

Teles AG Informationstechnologien Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
CEA	57 Neutral	€53.04M	7.25	83.64%	―	0.20%	―
CFC	50 Neutral	€10.31M	―	―	―	―	―
TLIK	38 Underperform	€1.88M	-0.86	―	―	―	―